Orphazyme expects to lay off 100 employees this year
At the end of July, Orphazyme completed its restructuring program, and according to the biotech company, it expects to have around 70 full-time employees at the end of the year. At the end of the first half-year, 180 people were employed.
BY CHRISTOFFER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT
It is no secret that Orphazyme has been forced to cut down its number of staff considerably after the FDA rejected the biotech company's key candidate arimoclomal as a treatment for metabolic disease Niemann-Pick type C, NPC.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme postpones financial report
For subscribers
Orphazyme to get rid of two thirds of employees
For subscribers
.jpg&w=384&q=75)
